Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

2 evidence topics · 2 sources

Preclinical pharmacology

“ivonescimab forms soluble complexes with VEGF dimers, leading to the enhanced binding avidity of ivonescimab to PD-1” (opens the source at this quote in a new tab)

Target engagement in the Chinese phase I study

“Ivonescimab occupancy on PD-1 sustained over 80% across the treatment period.” (opens the source at this quote in a new tab)
“Serum VEGF level was rapidly down-regulated after each administration.” (opens the source at this quote in a new tab)